N-(2-Hydroxyethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, 96%, 100mg

1-(4-Hydroxy-3-methoxy-5-nitrophenyl)ethanone, 95%, 100mg

(3-Chloro-5-(methoxycarbonyl)phenyl)boronic acid, 95.0%, 250mg

(3R,4S)-3-Hydroxy-4-phenylazetidin-2-one, 95.0%, 25g

2,6-Diiodophenol, 97%, 1g

1-Aminocyclopropanemethanol hydrochloride, 95.0%, 1g

m-Xileno, mínimo 98,5 %, para síntesis, 2,5 l, envase de vidrio

Methyl 3-amino-5-bromo-2-fluorobenzoate, 95.0%, 1g

6-(4-Ethylphenyl)-6-oxohexanoic acid, 97.0%, 1g

2-Hydroxybenzotrifluoride, 99.0%, 25g

Methyl 2-amino-4-methyl-3-oxopentanoate hydrochloride, 98%, 1g

(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)but-2-enamide (Dacomitinib Impurity), 98%, 50mg

3-Methyl-2-butenal, 98.0%, 5ml